The clinical significance of miR-590-3p in acute myeloid leukemia and potential regulatory mechanism based on bioinformatic prediction

Abstract Objectives Acute myeloid leukaemia (AML) usually has a poor prognosis, and an effective prognostic marker is needed. MicroRNAs (miRNAs) have potential as prognostic markers. Therefore, the prognostic diagnostic role and potential regulatory mechanisms of miR-590-3p in AML were investigated. Methods A total of 113 patients with AML and 83 healthy adults were included. miR-590-3p level was detected in AML patients before and after chemotherapy and in healthy adults using qRT-PCR. Correlating miR-590-3p levels with patient clinical data was assessed through the chi-squared test. The diagnostic potential of miR-590-3p was assessed by ROC curves. Survival of patients with different expression of miR-590-3p was assessed by Kaplan–Meier survival curves. COX regression analyzed the factors influencing the poor prognosis of AML. The potential pathways of miR-590-3p in AML progression were analyzed using GO and KEGG databases. Results In AML patients, miR-590-3p is upregulated, and miR-590-3p levels were notably decreased in complete remission after treatment. miR-590-3p has a good diagnostic value for AML. Patients with high miR-590-3p expression had shorter overall survival. And miR-590-3p was an independent influencing factor of poor prognosis in AML. miR-590-3p target genes are mainly enriched in the CDP-diacylglycerol biosynthesis process and the PI3K-Akt. Conclusions miR-590-3p has potential as a biomarker of poor prognosis in AML patients. miR-590-3p has the potential to modulate signaling pathways during AML development.